hydroxyurea has been researched along with Cancer of Lung in 87 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "In an effort to understand the molecular events contributing to the cytotoxicity activity of resveratrol (RSV), we investigated its effects on human lung adenocarcinoma epithelial cell line A549 at different concentrations." | 7.91 | Investigation into perturbed nucleoside metabolism and cell cycle for elucidating the cytotoxicity effect of resveratrol on human lung adenocarcinoma epithelial cells. ( Chen, QQ; Guo, JR; Lam, CWK; Li, Z; Wang, CY; Wong, VKW; Yao, MC; Zhang, W; Zhang, WJ, 2019) |
| "Potential efficacy of zileuton, a 5-LOX inhibitor, was evaluated for the reduction of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation." | 7.76 | Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model. ( Jensen, A; Karlage, KL; Mogalian, E; Myrdal, PB, 2010) |
| "The cytotoxic effects in vivo of hydroxyurea (HU) on murine fibrosarcoma (FSa) cells grown as pulmonary tumours were determined." | 7.66 | Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma pulmonary nodules. ( Grdina, DJ, 1982) |
| "The S-phase-specific cytotoxicity of hydroxyurea (HU) was tested on synchronized murine fibrosarcoma (FSa) cells lodged in the lungs of C3Hf/Bu mice." | 7.66 | Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma cells synchronized by centrifugal elutriation. ( Grdina, DJ; Peters, LJ; Sigdestad, CP, 1979) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 6.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "In an effort to understand the molecular events contributing to the cytotoxicity activity of resveratrol (RSV), we investigated its effects on human lung adenocarcinoma epithelial cell line A549 at different concentrations." | 3.91 | Investigation into perturbed nucleoside metabolism and cell cycle for elucidating the cytotoxicity effect of resveratrol on human lung adenocarcinoma epithelial cells. ( Chen, QQ; Guo, JR; Lam, CWK; Li, Z; Wang, CY; Wong, VKW; Yao, MC; Zhang, W; Zhang, WJ, 2019) |
| "Potential efficacy of zileuton, a 5-LOX inhibitor, was evaluated for the reduction of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation." | 3.76 | Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model. ( Jensen, A; Karlage, KL; Mogalian, E; Myrdal, PB, 2010) |
| "The cytotoxic effects in vivo of hydroxyurea (HU) on murine fibrosarcoma (FSa) cells grown as pulmonary tumours were determined." | 3.66 | Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma pulmonary nodules. ( Grdina, DJ, 1982) |
| "The S-phase-specific cytotoxicity of hydroxyurea (HU) was tested on synchronized murine fibrosarcoma (FSa) cells lodged in the lungs of C3Hf/Bu mice." | 3.66 | Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma cells synchronized by centrifugal elutriation. ( Grdina, DJ; Peters, LJ; Sigdestad, CP, 1979) |
| "BCNU, hydroxyurea, and imidazole carboxamide (DTIC) were administered to 89 patients with disseminated malignant melanoma." | 3.65 | Combination chemotherapy for disseminated malignant melanoma. ( Coltman, CA; Costanzi, JJ; Delaney, FC; Hoogstraten, B; Quagliana, JM; Vaitkevicius, VK, 1975) |
| "Hydroxyurea 500 mg was given orally each Monday, Wednesday, Friday starting 1 week before paclitaxel, and continuing until removal from study." | 2.68 | Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. ( Dulude, H; Evans, WK; Gertler, SZ; Goss, G; Huan, S; Logan, D; Stewart, DJ; Tomiak, EM; Yau, J, 1996) |
| "Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depletion of intracellular ribonucleotides." | 2.67 | A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. ( Carmichael, J; Ganesan, TA; Harris, AL; Philip, PA; Tonkin, K, 1994) |
| "Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin." | 2.67 | Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "The presence of pleural effusion is usually associated with uncontrolled leukocytosis and increased monocytes." | 2.66 | Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report. ( Fu, L; Hu, L; Hu, M; Zheng, B, 2020) |
| "When paclitaxel was used in combination with CGs, the highest antiproliferative effect was obtained when paclitaxel was administered first, followed by either digitoxin or MonoD." | 1.43 | Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel. ( Azad, N; Iyer, AK; Kaushik, V; Kulkarni, Y; O'Doherty, GA; Venkatadri, R; Wright, C; Yakisich, JS, 2016) |
| "Significant blood eosinophilia is uncommon in leiomyomas and should raise suspicion of malignant etiology for a pelvic mass." | 1.37 | Metastatic uterine leiomyosarcoma and eosinophilia. ( Cheung, WY; Ksienski, D, 2011) |
| "A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens." | 1.36 | Bevacizumab may be active in myelofibrosis. ( Dilana, K; Makrilia, N; Meletis, I; Nikolaidis, I; Stathopoulos, D; Syrigos, K; Xyla, V, 2010) |
| " Both S-29606 and S-30621 were dosed via nose-only inhalation 5 days a week, for 16 weeks, whereas Zileuton was administered orally." | 1.34 | Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation. ( Angersbach, BS; Karlage, K; Kuehl, PJ; Merrill, BA; Myrdal, PB; Wightman, PD, 2007) |
| "Surgery combined with chemotherapy was applied in 34 out of 178 patients (19." | 1.29 | Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD). ( Kietlińska, Z; Sablińska, B; Zieliński, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (55.17) | 18.7374 |
| 1990's | 15 (17.24) | 18.2507 |
| 2000's | 13 (14.94) | 29.6817 |
| 2010's | 10 (11.49) | 24.3611 |
| 2020's | 1 (1.15) | 2.80 |
| Authors | Studies |
|---|---|
| Easmon, J | 1 |
| Pürstinger, G | 1 |
| Heinisch, G | 1 |
| Roth, T | 1 |
| Fiebig, HH | 1 |
| Holzer, W | 1 |
| Jäger, W | 1 |
| Jenny, M | 1 |
| Hofmann, J | 1 |
| Li, Z | 1 |
| Chen, QQ | 1 |
| Lam, CWK | 1 |
| Guo, JR | 1 |
| Zhang, WJ | 1 |
| Wang, CY | 1 |
| Wong, VKW | 1 |
| Yao, MC | 1 |
| Zhang, W | 1 |
| Hu, L | 1 |
| Zheng, B | 1 |
| Fu, L | 1 |
| Hu, M | 1 |
| Chen, G | 2 |
| Magis, AT | 1 |
| Xu, K | 1 |
| Park, D | 1 |
| Yu, DS | 1 |
| Owonikoko, TK | 1 |
| Sica, GL | 1 |
| Satola, SW | 1 |
| Ramalingam, SS | 1 |
| Curran, WJ | 1 |
| Doetsch, PW | 1 |
| Deng, X | 1 |
| Chen, J | 1 |
| Qiao, Y | 1 |
| Shi, Y | 1 |
| Liu, W | 1 |
| Zeng, Q | 1 |
| Xie, H | 1 |
| Shi, X | 1 |
| Sun, Y | 1 |
| Liu, X | 1 |
| Li, T | 1 |
| Zhou, L | 1 |
| Wan, J | 1 |
| Xie, T | 1 |
| Wang, H | 1 |
| Wang, F | 1 |
| Oo, ZY | 1 |
| Proctor, M | 1 |
| Stevenson, AJ | 1 |
| Nazareth, D | 1 |
| Fernando, M | 1 |
| Daignault, SM | 1 |
| Lanagan, C | 1 |
| Walpole, S | 1 |
| Bonazzi, V | 1 |
| Škalamera, D | 1 |
| Snell, C | 1 |
| Haass, NK | 1 |
| Larsen, JE | 1 |
| Gabrielli, B | 1 |
| Yakisich, JS | 1 |
| Azad, N | 1 |
| Venkatadri, R | 1 |
| Kulkarni, Y | 1 |
| Wright, C | 1 |
| Kaushik, V | 1 |
| O'Doherty, GA | 1 |
| Iyer, AK | 1 |
| Nikolaidis, I | 1 |
| Makrilia, N | 1 |
| Xyla, V | 1 |
| Dilana, K | 1 |
| Stathopoulos, D | 1 |
| Meletis, I | 1 |
| Syrigos, K | 1 |
| Karlage, KL | 1 |
| Mogalian, E | 1 |
| Jensen, A | 1 |
| Myrdal, PB | 2 |
| Shinmura, K | 1 |
| Tao, H | 1 |
| Nagura, K | 1 |
| Goto, M | 1 |
| Matsuura, S | 1 |
| Mochizuki, T | 1 |
| Suzuki, K | 1 |
| Tanahashi, M | 1 |
| Niwa, H | 1 |
| Ogawa, H | 1 |
| Sugimura, H | 1 |
| Ksienski, D | 1 |
| Cheung, WY | 1 |
| Lambertz, N | 1 |
| Koehler, J | 1 |
| Schulte, DM | 1 |
| Kuehl, H | 1 |
| Wohlschlaeger, J | 1 |
| Hense, J | 1 |
| Schuler, M | 1 |
| Mueller, OM | 1 |
| Gunning, WT | 1 |
| Kramer, PM | 1 |
| Steele, VE | 1 |
| Pereira, MA | 1 |
| Huang, PH | 1 |
| You, JY | 1 |
| Hsu, HC | 1 |
| Biard, DS | 1 |
| Miccoli, L | 1 |
| Despras, E | 1 |
| Harper, F | 1 |
| Pichard, E | 1 |
| Créminon, C | 1 |
| Angulo, JF | 1 |
| Mabro, M | 1 |
| Louvet, C | 1 |
| André, T | 1 |
| Carola, E | 1 |
| Gilles-Amar, V | 1 |
| Artru, P | 1 |
| Krulik, M | 1 |
| de Gramont, A | 1 |
| BICKERS, JN | 1 |
| Durdux, C | 1 |
| Soria, G | 1 |
| Podhajcer, O | 1 |
| Prives, C | 1 |
| Gottifredi, V | 1 |
| Karlage, K | 1 |
| Kuehl, PJ | 1 |
| Angersbach, BS | 1 |
| Merrill, BA | 1 |
| Wightman, PD | 1 |
| Backlund, MG | 1 |
| Amann, JM | 1 |
| Johnson, DH | 1 |
| Edelman, MJ | 1 |
| Watson, D | 1 |
| Wang, X | 1 |
| Morrison, C | 1 |
| Kratzke, RA | 1 |
| Jewell, S | 1 |
| Hodgson, L | 1 |
| Mauer, AM | 1 |
| Gajra, A | 1 |
| Masters, GA | 1 |
| Bedor, M | 1 |
| Vokes, EE | 6 |
| Green, MJ | 1 |
| Ghosh, NK | 1 |
| Alberto, P | 2 |
| Berchtold, W | 1 |
| Sonntag, R | 1 |
| Barrelet, L | 2 |
| Jungi, F | 1 |
| Martz, G | 1 |
| Obrecht, P | 1 |
| Klemm-Mayer, H | 1 |
| Rasokat, H | 1 |
| Wagner, G | 1 |
| Shields, TW | 1 |
| Higgins, GA | 1 |
| Humphrey, EW | 1 |
| Matthews, MJ | 1 |
| Keehn, RJ | 1 |
| Kujawska, J | 1 |
| Krawczyk, K | 1 |
| Grdina, DJ | 2 |
| Zietz, S | 1 |
| Lessin, S | 1 |
| Grattarola, M | 1 |
| Desaive, C | 1 |
| Nicolini, C | 1 |
| Haraf, DJ | 4 |
| Drinkard, LC | 1 |
| Hoffman, PC | 3 |
| Ferguson, MK | 3 |
| Vogelzang, NJ | 1 |
| Watson, S | 1 |
| Lane, NJ | 1 |
| Golomb, HM | 3 |
| Zauber, NP | 1 |
| Vlad, LD | 1 |
| Philip, PA | 1 |
| Carmichael, J | 1 |
| Tonkin, K | 1 |
| Ganesan, TA | 1 |
| Harris, AL | 3 |
| Raschko, JW | 1 |
| Akman, SA | 1 |
| Leong, LA | 1 |
| Margolin, KA | 1 |
| Morgan, RJ | 1 |
| Newman, E | 1 |
| Somlo, G | 1 |
| Ahn, C | 1 |
| Doroshow, JH | 1 |
| Bitran, JD | 2 |
| Sablińska, B | 1 |
| Kietlińska, Z | 1 |
| Zieliński, J | 1 |
| Stewart, DJ | 1 |
| Tomiak, EM | 1 |
| Goss, G | 1 |
| Gertler, SZ | 1 |
| Logan, D | 1 |
| Huan, S | 1 |
| Yau, J | 1 |
| Dulude, H | 1 |
| Evans, WK | 1 |
| Kaba, SE | 1 |
| Kyritsis, AP | 1 |
| Hess, K | 1 |
| Yung, WK | 1 |
| Mercier, R | 1 |
| Dakhil, S | 1 |
| Jaeckle, KA | 1 |
| Levin, VA | 1 |
| Rioux, N | 1 |
| Castonguay, A | 1 |
| Larsson, L | 1 |
| Sydbom, A | 1 |
| Dahlén, SE | 1 |
| Eifel, PJ | 1 |
| Lamb, JR | 1 |
| Goehle, S | 1 |
| Ludlow, C | 1 |
| Simon, JA | 1 |
| Mac Manus, MP | 1 |
| Cavalleri, G | 1 |
| Ball, DL | 1 |
| Beasley, M | 1 |
| Rotstein, H | 1 |
| McKay, MJ | 1 |
| Scheer, AC | 2 |
| Wilson, RF | 2 |
| Costanzi, JJ | 2 |
| Loukas, D | 1 |
| Gagliano, RG | 1 |
| Griffiths, C | 1 |
| Barranco, S | 1 |
| Hansen, HH | 2 |
| Selawry, OS | 2 |
| Simon, R | 1 |
| Carr, DT | 1 |
| van Wyk, CE | 1 |
| Tucker, RD | 1 |
| Sealy, R | 1 |
| Petrovich, Z | 2 |
| Mietlowski, W | 1 |
| Ohanian, M | 2 |
| Cox, J | 2 |
| Sigdestad, CP | 1 |
| Peters, LJ | 1 |
| Bateman, AE | 1 |
| Steel, GG | 1 |
| Donelli, MG | 1 |
| Colombo, T | 1 |
| Broggini, M | 1 |
| Garattini, S | 1 |
| Chapuis, B | 1 |
| Garcia, B | 1 |
| Theiss, JC | 1 |
| Stoner, GD | 1 |
| Shimkin, MB | 1 |
| Twentyman, PR | 1 |
| Vaitkevicius, VK | 1 |
| Quagliana, JM | 1 |
| Hoogstraten, B | 1 |
| Coltman, CA | 1 |
| Delaney, FC | 1 |
| Lad, T | 1 |
| Schor, J | 1 |
| Mullane, M | 1 |
| Carroll, R | 1 |
| Chernicoff, D | 1 |
| Blough, R | 1 |
| Weidner, L | 1 |
| Balducci, L | 1 |
| Hardy, CL | 1 |
| Panje, WR | 1 |
| Weichselbaum, RR | 2 |
| Moormeier, JA | 1 |
| Ratain, MJ | 1 |
| Egorin, MJ | 1 |
| Mick, R | 1 |
| Vijayakumar, S | 1 |
| Krishnasamy, S | 1 |
| Jacobs, R | 1 |
| Cantwell, BM | 2 |
| Veale, D | 2 |
| Rivett, C | 1 |
| Ghani, S | 1 |
| Belani, CP | 1 |
| Eisenberger, M | 1 |
| Van Echo, D | 1 |
| Hiponia, D | 1 |
| Aisner, J | 1 |
| Axelson, JA | 1 |
| Clark, RH | 1 |
| Dimitrov, NV | 1 |
| Kerr, N | 1 |
| Upfold, A | 1 |
| McMillan, TJ | 1 |
| Rao, J | 1 |
| Hart, IR | 1 |
| Bonadonna, G | 1 |
| Tancini, G | 1 |
| Bajetta, E | 1 |
| Smithers, DW | 1 |
| Bhide, SV | 1 |
| Sirsat, MV | 1 |
| van der Merwe, AM | 1 |
| Falkson, G | 1 |
| Sandison, AG | 1 |
| van Dyk, JJ | 1 |
| Falkson, HC | 1 |
| Muggia, FM | 1 |
| Krezoski, SK | 1 |
| Ahmad, A | 1 |
| Goldin, A | 1 |
| Kalisher, L | 1 |
| Seiji, M | 1 |
| Takahashi, M | 1 |
| Carter, SK | 1 |
| Kaung, DT | 3 |
| Walsh, WS | 1 |
| Sbar, S | 2 |
| Patno, ME | 2 |
| Slack, NM | 1 |
| Jones, R | 1 |
| Creasey, WA | 1 |
| Capizzi, RL | 1 |
| DeConti, RC | 1 |
| LePar, E | 1 |
| Faust, DS | 1 |
| Brady, LW | 1 |
| Beckloff, GL | 2 |
| Muranyi-Kovacs, I | 1 |
| Rudali, G | 1 |
| Hussey, DH | 1 |
| Samuels, ML | 1 |
| Gottlieb, JA | 1 |
| Frei, E | 1 |
| Luce, JK | 1 |
| Connors, TA | 1 |
| Lerner, HJ | 1 |
| Godwin, MC | 1 |
| Campbell, RE | 1 |
| Templeton, JY | 1 |
| Swartzendruber, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer[NCT00070486] | Phase 2 | 140 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| 0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
| Intervention | days (Median) |
|---|---|
| Apricoxib Plus Docetaxel | 75 |
| Placebo Plus Docetaxel | 97 |
| Apricoxib Plus Pemetrexed | 103 |
| Placebo Plus Pemetrexed | 98 |
7 reviews available for hydroxyurea and Cancer of Lung
| Article | Year |
|---|---|
Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.
Topics: Adult; Antineoplastic Agents; Azacitidine; Diagnosis, Differential; Drug Therapy, Combination; Femal | 2020 |
[Cisplatin and derivatives with radiation therapy: for what clinical use?].
Topics: Animals; Anus Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Ph | 2004 |
Concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chicago; Cisplatin; | 1994 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.
Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cytarabine; Dacti | 1973 |
Lung cancer: perspectives and prospects.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyc | 1970 |
Rationale of combination chemotherapy based on preclinical experiments.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma; Cytarabine; Drug Synergism; Humans; Hydroxyur | 1973 |
23 trials available for hydroxyurea and Cancer of Lung
| Article | Year |
|---|---|
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Chemotherapy of small cell carcinoma of the lung: comparison of a cyclic alternative combination with simultaneous combinations of four and seven agents.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1981 |
Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.
Topics: Carcinoma; Clinical Trials as Topic; Humans; Hydroxyurea; Lomustine; Lung Neoplasms; Male; Neoplasm | 1982 |
[Radioisotope teletherapy with or without hydroxyurea in the treatment of inoperable lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Clinical Trials as Topic; Follow-Up Studies; Humans; Hydroxy | 1981 |
A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1995 |
A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dacarbazine; Female; Ga | 1994 |
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1994 |
Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 1996 |
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1997 |
Cancer of the lung and its response to non-surgical treatment.
Topics: Chemical Phenomena; Chemistry; Humans; Hydroxyurea; Lung Neoplasms; Palliative Care; Radiotherapy Do | 1975 |
Combination chemotherapy of advanced lung cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; | 1976 |
Clinical report of the treatment of locally advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Dose-Response Relation | 1977 |
Clinical research on the treatment of locally advanced lung cancer: final report of VALG Protocol 13 Limited.
Topics: Adenocarcinoma; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Top | 1978 |
A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Thera | 1975 |
Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; | 1992 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous | 1973 |
Combined radiotherapy and hydroxyurea in the management of lung cancer.
Topics: Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydroxyurea; Lung Neoplasms; Male; Radi | 1974 |
Hydroxyurea (NSC-32065) in therapy for nonresectable cancer of the lung.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Clinical Trials as Topic; Humans; Hydroxyurea; Lung Neoplasms; | 1968 |
Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
Topics: Anemia; Asparaginase; Azaserine; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug | 1970 |
Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065).
Topics: Adult; Aged; Blood Urea Nitrogen; Chondrosarcoma; Clinical Trials as Topic; Depression, Chemical; DN | 1970 |
57 other studies available for hydroxyurea and Cancer of Lung
| Article | Year |
|---|---|
Synthesis, cytotoxicity, and antitumor activity of copper(II) and iron(II) complexes of (4)N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines.
Topics: Antineoplastic Agents; Apoptosis; Body Weight; Burkitt Lymphoma; Carcinoma, Large Cell; Cell Cycle; | 2001 |
Investigation into perturbed nucleoside metabolism and cell cycle for elucidating the cytotoxicity effect of resveratrol on human lung adenocarcinoma epithelial cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Cell Cycle; Cell Survival; Deoxyribonucleotides; Dose-Response R | 2019 |
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cellular Senescence; DNA Breaks, Double-Str | 2018 |
ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Binding Sites; Camptothecin; | 2018 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, | 2019 |
Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Digitoxin; Drug Synergism; Hexoses; Hum | 2016 |
Bevacizumab may be active in myelofibrosis.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model.
Topics: Adenoma; Administration, Inhalation; Animals; Benzo(a)pyrene; Chemistry, Pharmaceutical; Dosage Form | 2010 |
Suppression of hydroxyurea-induced centrosome amplification by NORE1A and down-regulation of NORE1A mRNA expression in non-small cell lung carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell | 2011 |
Metastatic uterine leiomyosarcoma and eosinophilia.
Topics: Antineoplastic Agents; Benzamides; Dyspnea; Eosinophilia; Fatal Outcome; Female; Humans; Hydroxyurea | 2011 |
Multivisceral systemic metastases from an intracranial anaplastic meningioma: a case report and review of literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Brain Neoplasms; Carcinoma; Fatal Outcome; Female; Humans; Hydr | 2011 |
Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice.
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Dose-Response Relationship, Drug; Female; Hydroxyurea | 2002 |
Extensive pulmonary infiltration by leukemic blasts successfully treated with hydroxyurea--a case report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Blast Crisis; Diagnosis, Differential; Humans; Hydroxyu | 2002 |
Participation of kin17 protein in replication factories and in other DNA transactions mediated by high molecular weight nuclear complexes.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Division; Co | 2003 |
PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CARCINOMA OF THE LUNG.
Topics: Adult; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Drug Therapy; Humans; Hydroxyurea | 1964 |
P21Cip1/WAF1 downregulation is required for efficient PCNA ubiquitination after UV irradiation.
Topics: Antineoplastic Agents; Aphidicolin; Cell Cycle; Cell Proliferation; Cells, Cultured; Colorectal Neop | 2006 |
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
Topics: Adenoma; Administration, Inhalation; Administration, Oral; Animals; Benzo(a)pyrene; Disease Models, | 2007 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; C | 2008 |
Drug-induced biochemical markers of cancer in cervical carcinoma cells.
Topics: Alkaline Phosphatase; Butyrates; Butyric Acid; Carcinoembryonic Antigen; Chorionic Gonadotropin; Cho | 1982 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female | 1984 |
Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma pulmonary nodules.
Topics: Animals; Cell Division; Cell Survival; Female; Fibrosarcoma; Flow Cytometry; Hydroxyurea; Interphase | 1982 |
FPi analysis. II. Use of the method to monitor the in vivo kinetics of cell populations perturbed by hydroxyurea.
Topics: Animals; Bone Marrow; Cell Division; Hydroxyurea; Lung Neoplasms; Mathematics; Melanoma; Mice; Mice, | 1980 |
Myeloproliferative disorders in two New Jersey families.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; beta-Thalassemia; Carcinoma, Non-Small-Cell Lung; Female; | 1995 |
Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD).
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chorioca | 1993 |
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Arachidonic Acid; Aspirin; Body Weight; Carcinogens; Drug Screenin | 1998 |
Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells.
Topics: Histamine H1 Antagonists; Histamine Release; Humans; Hydroxyurea; Indazoles; Leukotriene Antagonists | 1999 |
Thymidine incorporation is highly predictive of colony formation and can be used for high-throughput screening.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Chickens; CHO Cells; Colonic Neoplasms | 2001 |
Exacerbation, then clearance, of mutation-proven Darier's disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Calcium-Transporting ATPases; Carcino | 2001 |
Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies: a preliminary report.
Topics: Adult; Bleomycin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Therapy, Combination; | 1976 |
Phase-specific cytotoxicity in vivo of hydroxyurea on murine fibrosarcoma cells synchronized by centrifugal elutriation.
Topics: Animals; Cell Count; Cell Division; Cell Survival; Centrifugation; Colony-Forming Units Assay; Femal | 1979 |
The proliferative state of clonogenic cells in the Lewis lung tumour after treatment with cytotoxic agents.
Topics: Animals; Cell Cycle; Cell Division; Cell Survival; Clone Cells; Culture Techniques; Cyclophosphamide | 1978 |
Differential distribution of antitumor agents in primary and secondary tumors.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Cyclophosphamide; Daunorubici | 1977 |
Murine pulmonary adenoma bioassay of potentially effective agents against slow-growing solid tumors.
Topics: Adenoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Cytarabine; | 1977 |
Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide.
Topics: Animals; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Hydroxyurea; Lun | 1977 |
Combination chemotherapy for disseminated malignant melanoma.
Topics: Adolescent; Adult; Aged; Amides; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Therapy, C | 1975 |
High proliferation of early hemopoietic progenitors in tumor-bearing mice.
Topics: Anemia; Animals; Bone Marrow; Carcinoma; Cell Division; Hematopoiesis; Hematopoietic Cell Growth Fac | 1992 |
5-Fluorouracil with oral leucovorin and hydroxyurea and concomitant radiotherapy for stage III non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1990 |
Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc | 1989 |
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis-Related Groups; Drug Evaluation; Female; Huma | 1987 |
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 1987 |
Phase 1 study of high-dose hydroxyurea in lung cancer.
Topics: Aged; DNA Damage; Drug Evaluation; Female; Humans; Hydroxyurea; Lung Neoplasms; Male; Middle Aged; T | 1988 |
Enhancement of experimental metastasis by pretreatment of tumour cells with hydroxyurea.
Topics: Animals; Cell Division; Cell Line; Cell Survival; Clone Cells; DNA, Neoplasm; Hydroxyurea; Lung Neop | 1986 |
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
Topics: Adenocarcinoma; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Doxorubicin; Fluoroura | 1973 |
Chemotherapy for metastatic teratomas of the testis.
Topics: Adult; Antineoplastic Agents; Dactinomycin; Dysgerminoma; Follow-Up Studies; Humans; Hydroxyurea; Lu | 1972 |
Delayed effects of a single treatment of hydroxyurea to newborn mice.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Animals, Newborn; Fatty Liver; Female; Hydroxyurea; Lu | 1973 |
Cell kinetic studies in patients with small cell carcinoma of the lung.
Topics: Autoradiography; Biopsy; Bone Marrow; Carcinoma, Small Cell; Cell Division; Cyclohexanes; Cyclophosp | 1974 |
Hydroxyurea and bronchogenic carcinoma.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Humans; Hydroxyurea; Lung Neoplasms; Male; Middle Aged | 1974 |
Malignant melanoma with adjacent intraepidermal proliferation.
Topics: Adult; Chromomycin A3; Ethnicity; Female; Heel; Humans; Hydroxyurea; Lentigo; Lip Neoplasms; Lung Ne | 1974 |
Some thoughts on surgical adjuvant studies in lung cancer.
Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Combinatio | 1973 |
Clinical evaluation of the adjunctive use of hydroxyurea (NSC-32065) in radiation therapy of carcinoma of the lung. A comparative study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Female; Humans; Hydroxyurea | 1967 |
Comparative study of carcinogenic activity of hydroxyurea and urethane in XVII-G mice.
Topics: Animals; Carcinogens; Hydroxyurea; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neopl | 1972 |
Combined hydroxyurea and radiotherapy: a new dosage schedule.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms; | 1972 |
Dose-schedule studies with hydroxyurea (NSC-32065) in malignant melanoma.
Topics: Administration, Oral; Adult; Amides; Female; Humans; Hydroxyurea; Imidazoles; Injections, Intravenou | 1971 |
Treatment of nonresectable cancer of the lung with hydroxyurea (NSC-32065) given intermittently.
Topics: Administration, Oral; Cyclophosphamide; Humans; Hydroxyurea; Injections, Intravenous; Lung Neoplasms | 1971 |
An outline of cancer chemotherapy.
Topics: Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Asparaginase; Breast Neoplasms; | 1971 |
Concomitant hydroxyurea and radiotherapy in the preoperative management of locally advanced lung cancer.
Topics: Aged; Autopsy; Female; Humans; Hydroxyurea; Leukocyte Count; Leukocytes; Lung Neoplasms; Male; Middl | 1970 |
Effect of chemotherapeutic agents on chromosomes of patients with lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Bronchogenic; Chromosome Aberrations; Chromosomes; Cyclopho | 1969 |